Casdin Capital’s Decibel Therapeutics, Inc. Common Stock DBTX Stock Holding History

Casdin Capital’s Portfolio DBTX Stock Details DBTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-330,000	Closed	-$1M	–	52
2022 Q1	$1M	Sell	330,000 -840,048	-72%	-$3.22M	0.05%	46
2021 Q4	$5.44M	Hold	1,170,048	–	–	0.15%	49
2021 Q3	$9.02M	Sell	1,170,048 -1,373	-0.1%	-$10.5K	0.22%	46
2021 Q2	$10.1M	Buy	1,171,421 +25,000	+2%	+$221K	0.26%	43
2021 Q1	$13M	Buy	+1,146,421	New	+$18M	0.39%	38

Other funds holding DBTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.7B AUM 39.36% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Casdin Capital's DBTX Position: Q2 2022 in Review

Casdin Capital sold out of Decibel Therapeutics, Inc. Common Stock (DBTX) in Q2 2022, closing a stake of 330,000 shares — an estimated $1M sold.

Casdin Capital first reported a position in DBTX in Q1 2021 and held it in 5 quarters. The position peaked at $13M in Q1 2021. 42 funds tracked by Wall St. Rank hold DBTX as of Q2 2022.

Casdin Capital reported no remaining Decibel Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Casdin Capital sold 330,000 Decibel Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $1M.
Casdin Capital first reported a position in Decibel Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Casdin Capital's Decibel Therapeutics, Inc. Common Stock position peaked at $13M in Q1 2021.
42 funds tracked by Wall St. Rank held Decibel Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Casdin Capital's 13F filing for Q2 2022, filed 15 Aug 2022.